Details for New Drug Application (NDA): 212781
✉ Email this page to a colleague
The generic ingredient in RANOLAZINE is ranolazine. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ranolazine profile page.
Summary for 212781
| Tradename: | RANOLAZINE |
| Applicant: | Arthur Grp |
| Ingredient: | ranolazine |
| Patents: | 0 |
Suppliers and Packaging for NDA: 212781
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 212781 | ANDA | AvKARE | 42291-773 | 42291-773-60 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (42291-773-60) |
| RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 212781 | ANDA | AvKARE | 42291-774 | 42291-774-60 | 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (42291-774-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 500MG | ||||
| Approval Date: | Mar 23, 2020 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 1GM | ||||
| Approval Date: | Mar 23, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
